Singapore's Health Sciences Authority (HSA) just raised the bar for AI-powered medical devices. In this episode, we break down the critical updates from last week's new regulatory guidelines and explore what they mean for the future of digital health in the ASEAN region. This move solidifies Singapore’s status as a top-tier regulator but introduces complex new hurdles for innovators.

We examine the challenges through the lens of a startup with a groundbreaking AI diagnostic tool. Their path to market has fundamentally changed, now requiring a comprehensive "Algorithm Change Protocol" before they can even get approved. This new lifecycle approach presents a major challenge, but also a hidden opportunity to build trust and a competitive edge.

Key Takeaways for This Episode:

- What is an "Algorithm Change Protocol" and why is it now mandatory for my AI device in Singapore?

- How does the HSA's new guidance on "continuous learning" algorithms impact my product roadmap?

- Are my current post-market surveillance plans adequate for these new, stricter requirements?

- How can I use Singapore's new framework as a benchmark to accelerate approval in other ASEAN markets?

- What are the key data governance and cybersecurity requirements buried in the new guidelines?

- Does my AI-powered diagnostic tool now face a higher risk classification in Singapore?

Navigating the global MedTech landscape requires specialized expertise. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, using local experts and advanced AI tools to streamline your market access. Whether you're a startup or a multinational, we provide the strategy and support to get your products to market efficiently. Contact us at [email protected] or visit https://pureglobal.com/ to learn more.